Prescribed glucocorticoids
Typical setting: Oral, injected, inhaled, topical or interacting steroid exposure.
Pharmacological glucocorticoid activity produces the phenotype and suppresses CRH, ACTH and endogenous adrenal cortisol.
Cushing syndrome module
Understand Cushing syndrome as chronic glucocorticoid excess causing catabolism, insulin resistance, fat redistribution, mineralocorticoid effects, immune suppression and loss of normal cortisol feedback.
Clinically reviewed by Mark · NMC-registered nurse
Aetiology
Separate exogenous exposure from ACTH-dependent and ACTH-independent endogenous sources.
Typical setting: Oral, injected, inhaled, topical or interacting steroid exposure.
Pharmacological glucocorticoid activity produces the phenotype and suppresses CRH, ACTH and endogenous adrenal cortisol.
Typical setting: Cushing disease, the common endogenous ACTH-dependent source.
Autonomous ACTH stimulates both adrenals despite cortisol feedback.
Typical setting: Neuroendocrine tumours such as small-cell lung or bronchial carcinoid.
Tumour-derived ACTH drives adrenal cortisol and androgen synthesis outside pituitary control.
Typical setting: Adenoma, carcinoma or bilateral nodular disease.
Cortisol secretion is ACTH-independent, so pituitary ACTH becomes suppressed by feedback.
Typical setting: Severe depression, alcohol excess, obesity or major physiological stress.
HPA activation can create biochemical and phenotypic overlap, requiring expert confirmation before tumour localisation.
Mechanism chain
Persistent cortisol action shifts metabolism towards catabolism, insulin resistance and vascular and immune dysfunction.
Exogenous glucocorticoid or endogenous ACTH/adrenal disease produces sustained receptor activation and loss of the normal rhythm.
Hepatic gluconeogenesis increases while muscle and fat become insulin resistant, causing hyperglycaemia.
Keep exploring